Asset
Tasimelteon
Vanda Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (25)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03291041 | phase2 | completed | 2016-07-01 | 2017-11-01 | Vanda Pharmaceuticals | A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder |
| NCT01402076 | phase1 | completed | 2011-08-01 | 2011-08-01 | Vanda Pharmaceuticals | A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects |
| NCT05572281 | phase1 | completed | 2022-05-18 | 2022-06-15 | Vanda Pharmaceuticals | Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers |
| NCT01477619 | phase1 | completed | 2011-11-01 | 2012-01-01 | Vanda Pharmaceuticals | Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects |
| NCT01163032 | phase3 | completed | 2010-08-01 | 2012-11-01 | Vanda Pharmaceuticals | Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 205677 | NDA | VANDA PHARMACEUTICALS INC |
| NDA 214517 | NDA | VANDA PHARMACEUTICALS INC |
Marketed products (3)
- HETLIOZ
- HETLIOZ LQ
- HETLIOZ LQ